↑ 疾患リストへ ← 戻る

 74. 下垂体性PRL分泌亢進症 [臨床試験数:15,薬物数:25(DrugBank:10),標的遺伝子数:16,標的パスウェイ数:14] 

Searched query = "Prolactin secreting pituitary adenoma", "Pituitary PRL secretion hyperthyroidism", "Prolactinoma", "Prolactin secreting adenoma"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 11/20/2019, 11/21/2019. Trials are sorted by Date_enrolment from most recent to oldest in the table.

Search in Page    e.g. "Phase 3", "Not recruiting", "Japan"    Synonyms (DrugBank) were also searched for.
No.TrialIDDate_
enrollement
Last_Refreshed_
on
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT04107480June 21, 201914 October 2019PRolaCT - Three Prolactinoma RCTsPRolaCT - Three Multicenter Prolactinoma Randomized Clinical TrialsProlactinoma;Prolactin-Producing Pituitary TumorProcedure: Endoscopic trans-sphenoidal adenoma resection;Drug: Dopamine AgonistsLeiden University Medical CenterRecruiting18 YearsN/AAll660Phase 4Netherlands
2NCT03717454December 1, 20183 December 2018Dopamine D2 Receptors(D2R) Imaging in ProlactinomasThe Predictive Value of Positron Emission Tomography-Magnetic Resonance (PET-MR) Mediated Dopamine D2 Receptors Imaging in the Drug Therapy of of Prolactinomas.ProlactinomaOther: Surgery;Drug: Drug treatmentZhebao WuXinqiao Hospital of Chongqing;First Hospital of China Medical University;Beijing Tiantan Hospital;First Affiliated Hospital of Wenzhou Medical University;First Affiliated Hospital of Fujian Medical University;Peking Union Medical College Hospital;Huashan Hospital;Chinese PLA General HospitalNot recruiting18 Years65 YearsAll50N/A
3NCT03457389October 1, 20181 October 2018Comparison of Treatment Outcome of Cabergoline According to Target Prolactin Levels in Patients With ProlactinomaComparison of Treatment Outcome of Cabergoline According to Target Prolactin Levels in Patients With Prolactinoma: A Prospective, Randomized, Open Label, Active-controlled, Clinical TrialPituitary Adenoma;Prolactinoma;Pituitary Tumor;Recurrence TumorDrug: CabergolineSeoul National University HospitalNot recruiting19 YearsN/AAll68N/AKorea, Republic of
4NCT03038308September 16, 201616 September 2019Treatment of Hyperprolactinemia With the Non-ergoline Dopamine Agonist RopiniroleTreatment of Hyperprolactinemia With the Non-ergoline Dopamine Agonist Ropinirole: A Dose Escalation Study of Efficacy and TolerabilityHyperprolactinemia;ProlactinomaDrug: RopiniroleColumbia UniversityNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)Recruiting18 Years70 YearsAll26Phase 1/Phase 2United States
5NCT03353025January 1, 201616 December 2017Study on Therapy of Non-invasive ProlactinomaProspective Randomized Clinical Study on Transsphenoidal or Dopamine Drugs Therapy Treat Non-invasive ProlactinomaProlactinomaProcedure: transsphenoidal surgery treatment;Drug: dopamine agonist treatmentFirst Affiliated Hospital, Sun Yat-Sen UniversityRecruiting18 Years60 YearsAll394N/AChina
No.TrialIDDate_
enrollement
Last_Refreshed_
on
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
6ChiCTR-ONC-120021942012-05-0118 April 2017Artery Endothelium Function, Carotid Artery Intima-Media Thickness and Cardiac Mass and Function after Long-Term Control of HyperprolactimiaArtery Endothelium Function, Carotid Artery Intima-Media Thickness and Cardiac Mass and Function after Long-Term Control of Hyperprolactimiaprolactinomapatients with prolactinoma:treatment with bromocriptine ;First affiliated hospital of Sun Yat-sen UniversityNot Recruiting1355Bothpatients with prolactinoma:40;Other
7NCT01344291July 201119 February 2015Turmeric Effect on Reduction of Serum Prolactin and Related Hormonal Change and Adenoma Size in Prolactinoma PatientsHyperprolactinomaDrug: CurcuminMashhad University of Medical SciencesRecruiting20 Years45 YearsFemale30Phase 1Iran, Islamic Republic of
8NCT01088763March 201019 February 2015Gamma-Secretase Inhibitor RO4929097 in Treating Young Patients With Relapsed or Refractory Solid Tumors, CNS Tumors, Lymphoma, or T-Cell LeukemiaA PHASE 1/2 STUDY OF RO4929097, AN ORAL SMALL MOLECULE INHIBITOR OF GAMMA-SECRETASE, IN CHILDREN WITH RELAPSED/REFRACTORY SOLID OR CNS TUMORS, LYMPHOMA, OR T-CELL LEUKEMIAChildhood Atypical Teratoid/Rhabdoid Tumor;Childhood Central Nervous System Choriocarcinoma;Childhood Central Nervous System Germinoma;Childhood Central Nervous System Mixed Germ Cell Tumor;Childhood Central Nervous System Teratoma;Childhood Central Nervous System Yolk Sac Tumor;Childhood Choroid Plexus Tumor;Childhood Craniopharyngioma;Childhood Ependymoblastoma;Childhood Grade I Meningioma;Childhood Grade II Meningioma;Childhood Grade III Meningioma;Childhood Infratentorial Ependymoma;Childhood Medulloepithelioma;Childhood Mixed Glioma;Childhood Oligodendroglioma;Childhood Supratentorial Ependymoma;Gonadotroph Adenoma;Pituitary Basophilic Adenoma;Pituitary Chromophobe Adenoma;Pituitary Eosinophilic Adenoma;Prolactin Secreting Adenoma;Recurrent Childhood Acute Lymphoblastic Leukemia;Recurrent Childhood Anaplastic Large Cell Lymphoma;Recurrent Childhood Brain Stem Glioma;Recurrent Childhood Central Nervous System Embryonal Tumor;Recurrent Childhood Cerebellar Astrocytoma;Recurrent Childhood Cerebral Astrocytoma;Recurrent Childhood Ependymoma;Recurrent Childhood Grade III Lymphomatoid Granulomatosis;Recurrent Childhood Large Cell Lymphoma;Recurrent Childhood Lymphoblastic Lymphoma;Recurrent Childhood Medulloblastoma;Recurrent Childhood Pineoblastoma;Recurrent Childhood Small Noncleaved Cell Lymphoma;Recurrent Childhood Spinal Cord Neoplasm;Recurrent Childhood Subependymal Giant Cell Astrocytoma;Recurrent Childhood Supratentorial Primitive Neuroectodermal Tumor;Recurrent Childhood Visual Pathway and Hypothalamic Glioma;Recurrent Childhood Visual Pathway Glioma;Recurrent Pituitary Tumor;Recurrent/Refractory Childhood Hodgkin Lymphoma;T-cell Childhood Acute Lymphoblastic Leukemia;T-cell Large Granular Lymphocyte Leukemia;TSH Secreting Adenoma;Unspecified Childhood Solid Tumor, Protocol SpecificDrug: gamma-secretase/Notch signalling pathway inhibitor RO4929097;Other: diagnostic laboratory biomarker analysis;Other: pharmacological study;Drug: dexamethasoneNational Cancer Institute (NCI)Not recruiting1 Year21 YearsBoth129Phase 1United States;Canada
9NCT01620138March 201019 October 2017Response to Cabergoline and Pasireotide in Non-functioning Pituitary Adenomas and Resistant ProlactinomasSomatostatin and Dopamine Receptors Expression in Non-functioning Pituitary Adenomas and Resistant Prolactinomas: Correlation With in Vitro and in Vivo Responsiveness to Somatostatin Analogs and Dopamine AgonistNon-functioning Pituitary Adenomas;ProlactinomasDrug: Pasireotide;Drug: cabergolineUniversidade Federal do Rio de JaneiroNot recruiting18 YearsN/AAll21Phase 2/Phase 3Brazil
10EUCTR2009-010918-30-IE11/08/200919 March 2012Effect of growth hormone replacement on cortisol-to-cortisone interconversion in hypopituitary patients with growth hormone deficiency and the influence of different aetiologies of hypopituitarism.Effect of growth hormone replacement on cortisol-to-cortisone interconversion in hypopituitary patients with growth hormone deficiency and the influence of different aetiologies of hypopituitarism.20 patients with hypopituitarism including growth hormone deficiency will be evaluated both on growth hormone replacement and when they have been off it for a 2 month period. They will have been prescribed growth hormone replacement in the form of Genotropin/Genotropin Miniquick/Norditropin prior to inclusion in this study as part of their routine clinical care.
MedDRA version: 9.1 Level: LLT Classification code 10021067 Term: Hypopituitarism
MedDRA version: 9.1 Level: LLT Classification code 10033662 Term: Panhypopituitarism
MedDRA version: 9.1 Level: LLT Classification code 10056438 Term: Growth hormone deficiency
MedDRA version: 9.1 Level: LLT Classification code 10011318 Term: Craniopharyngioma
MedDRA version: 9.1 Level: LLT Classification code 10036832 Term: Prolactinoma
MedDRA version: 9.1 Level: LLT Classification code 10011651 Term: Cushing's disease
MedDRA version: 9.1 Level: LLT Classification code 10035104 Term: Pituitary tumour
MedDRA version: 9.1 Level: LLT Classification code 10061538 Term: Pituitary tumour benign
Trade Name: Genotropin 5.3mg
Pharmaceutical Form: Powder and solvent for solution for injection
INN or Proposed INN: SOMATROPIN
CAS Number: 12629015
Concentration unit: mg milligram(s)
Concentration type: up to
Concentration number: 5.3-
Trade Name: Genotropin 12mg
Pharmaceutical Form: Powder and solvent for solution for injection
INN or Proposed INN: SOMATROPIN
CAS Number: 12629015
Concentration unit: mg milligram(s)
Concentration type: up to
Concentration number: 12-
Trade Name: Genotropin Miniquick 0.2mg
Pharmaceutical Form: Powder and solvent for solution for injection
INN or Proposed INN: SOMATROPIN
CAS Number: 12629015
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 0.2-
Trade Name: Genotropin Miniquick 0.4mg
Pharmaceutical Form: Powder and solvent for solution for injection
INN or Proposed INN: SOMATROPIN
CAS Number: 12629015
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 0.4-
Trade Name: Genotropin Miniquick 0.6mg
Pharmaceutical Form: Powder and solvent for solution for injection
INN or Proposed INN: SOMATROPIN
CAS Number: 12629015
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 0.6-
Trade Name: Genotropin Miniquick 0.8mg
Pharmaceutical Form: Powder and solvent for solution for injection
INN or Proposed INN: SOMATROPIN
CAS Number: 12629015
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 0.8-
Trade Name: Genotropin Miniquick 1.0mg
Pharmaceutical Form: Powder and solvent for solution for injection
INN or Proposed INN: SOMATROPIN
CAS Number: 12629015
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 1.0-
Trade Name: Genotropin Miniquick 1.2mg
Pharmaceutical Form: Powder and solvent for solution for injection
INN or Proposed INN: SOMATROPIN
CAS Number: 12629015
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 1.2-
Amar Agha, Beaumont HospitalAuthorisedFemale: yes
Male: yes
20Ireland
No.TrialIDDate_
enrollement
Last_Refreshed_
on
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
11NCT00939523July 200911 February 2019Targeted Therapy With Lapatinib in Patients With Recurrent Pituitary Tumors Resistant to Standard TherapyTargeted Therapy With Lapatinib in Patients With Recurrent Pituitary Tumors Resistant to Standard TherapyPituitary Adenomas;ProlactinomasDrug: LapatinibCedars-Sinai Medical CenterNot recruiting18 YearsN/AAll12Phase 2United States
12EUCTR2008-007348-32-FR06/05/200922 August 2016An open label, multicenter, single arm study of pasireotide LAR in patients with rare tumors of neuroendocrine origin - NAAn open label, multicenter, single arm study of pasireotide LAR in patients with rare tumors of neuroendocrine origin - NAThe following tumors are included: 1. NETs of the pancreas or duodenum: Insulinoma, Gastrinoma, VIPoma, glucagonoma, 2. Pituitary NETs: Thyrotropic-pituitary adenoma (TSH), Gonadotropic adenoma, Prolactinoma (PRL) and non-functioning pituitary adenoma (NFPA) 3. Ectopic ACTH-secreting (EAS) tumors 4. Nelson’s syndrome
MedDRA version: 9.1 Level: LLT Classification code 10062476 Term: Neuroendocrine tumor
Product Name: pasireotide
Product Code: SOM230
Pharmaceutical Form: Powder and solvent for suspension for injection
INN or Proposed INN: Pasireotide
Current Sponsor code: SOM230
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 20-
Product Name: pasireotide
Product Code: SOM230
Pharmaceutical Form: Powder and solvent for suspension for injection
INN or Proposed INN: Pasireotide
Current Sponsor code: SOM230
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 40-
Product Name: pasireotide
Product Code: SOM230
Pharmaceutical Form: Solution for injection
INN or Proposed INN: Pasireotide
Current Sponsor code: SOM230
Concentration unit: µg microgram(s)
Concentration type: equal
Concentration number: 600-
Novartis Pharma Services AGNot RecruitingFemale: yes
Male: yes
100Phase 2France;Spain;Germany;Italy
13EUCTR2006-007036-95-DE02/07/200819 March 2012Monocenter, double blinded, exploratory, randomized, study investigating the influence of Pasireotide on the hormonal activity of Prolactinomas - proof of concept studyMonocenter, double blinded, exploratory, randomized, study investigating the influence of Pasireotide on the hormonal activity of Prolactinomas - proof of concept studyProlactinoma
MedDRA version: 9.1 Level: LLT Classification code 10036832 Term: Prolactinoma
Product Code: SOM230
Pharmaceutical Form: Injection*
INN or Proposed INN: Pasireotide
Current Sponsor code: SOM230
Concentration unit: µg microgram(s)
Concentration type: equal
Concentration number: 600-
Product Code: SOM230
Pharmaceutical Form: Injection*
INN or Proposed INN: Pasireotide
Current Sponsor code: SOM230
Concentration unit: µg microgram(s)
Concentration type: equal
Concentration number: 900-
Universitätsklinikum Essen - Zentrum für Innere Medizin - Klinik für EndokrinologieNot RecruitingFemale: yes
Male: yes
Germany
14NCT00460616January 200719 February 2015Cardiac Valve Complications in Prolactinomas Treated With CabergolineObservational Study to Investigate the Prevalence of Cardiac Abnormalities and Valvular Regurgitation in Patients With Prolactinomas Treated Chronically With CabergolineProlactinomasDrug: CabergolineFederico II UniversityNot recruiting18 Years65 YearsBoth50Phase 4Italy
15NCT00697814June 200419 February 2015Clomiphene in Males With Prolactinomas and Persistent HypogonadismRecovery of Gonadal Function by Clomiphene in Males With Prolactinomas and Persistent HypogonadismHypogonadotropic Hypogonadism;ProlactinomaDrug: Clomiphene citrateFederal University of São PauloNot recruiting18 Years70 YearsMale15Phase 2Brazil

先頭へ